Introduction
============

Increased survival from breast cancer as a result of advances in both diagnosis and treatment has meant that 'quality-of-life' measures are becoming an increasingly important indicator of treatment success, as opposed to mortality rates alone \[[@ref1]\]. Since breast reconstruction after mastectomy is associated with significant improvements in both psychosocial outcomes and body image, such surgery has become a key consideration in the multidisciplinary management of breast cancer \[[@ref2]\]. Consequently, novel techniques and devices in the field of breast reconstruction surgery have been developed with the aim of improving outcomes and meeting patient expectations.

Implant-based breast reconstruction (IBBR) is the most commonly used technique and offers a safe, simple approach to reconstructive surgery, without the need for a long operation or use of donor site tissue \[[@ref3], [@ref4]\] Traditionally, a two-stage 'sub-muscular' technique has been used, in which, following mastectomy, a 'pocket' is developed under the chest wall musculature into which an expander-type implant is placed and the skin flaps are closed over it. The expander implant is then sequentially inflated with saline over a period of weeks until the desired size is reached, after which it is exchanged for a definitive or 'fixed volume' implant as a second procedure \[[@ref2]\]. The nature of the muscular pocket can either be 'total' (in which the pectoralis major, serratus anterior and rectus abdominalis muscle or fascia are elevated and sutured together anterior to the implant); or 'partial', where only the upper pole is covered by the pectoralis major \[[@ref5]--[@ref7]\].

Both of these traditional sub-muscular techniques are, however, associated with disadvantages. With partial sub-muscular coverage, the inferior pole is covered only by the skin of the mastectomy flap, predisposing to implant extrusion or exposure, particularly in the presence of necrosis or infection \[[@ref7], [@ref8]\]. While total sub-muscular coverage of the implant protects it from potential exposure, it requires extensive muscular dissection and may cause pain during the expansion phase. Both techniques can result in lack of control over the position of the inframammary fold (IMF), in a flat unnatural look or make it difficult to achieve a natural looking ptosis \[[@ref9], [@ref10]\].

The 'lower pole support' (LPS) technique
========================================

In an attempt to overcome some of these limitations, the traditional sub-muscular technique has been modified in recent years through the additional use of novel materials as adjuncts. Whilst still placing the implant beneath the pectoralis muscle, the 'LPS' technique additionally employs the use of a biological or synthetic mesh to cover the lower pole of the implant by suturing it to the IMF and the lower border of the pectoralis major muscle \[[@ref9], [@ref11]\]. This technique has the advantage not only of providing support to the lower pole of the implant by acting as a sling but also increases the overall size of the pocket such that, in selected cases, there is the option to proceed directly to a one-stage procedure using a fixed volume implant \[[@ref12]\]. When first introduced, the mesh used for this technique was the acellular dermal matrix (ADM) 'Alloderm', which is derived from human cadaveric dermis \[[@ref13], [@ref14]\]. Since then, multiple alternative products have entered the market -- an overview of which is provided below.

Materials currently used for the 'LPS' technique
================================================

Acellular matrices
------------------

ADMs are sterile, acellular, biological pieces of material derived from human or animal skin, in which the dermis is stripped of the cellular components, leaving a structurally intact and biochemically inert, extracellular matrix \[[@ref15]\]. While the human skin-derived ADM, 'Alloderm' was the first ADM to be described in the literature, multiple ADMs derived from both allogenic and xenograft (porcine and bovine) donor sources are now in use. These products differ in their processing and as a result have differences in handling, incorporation, shelf life and cost. In addition to ADMs, de-cellularised tissue derived from other tissue sources, such as the pericardium and peritoneum, have also been developed which have similar properties \[[@ref16], [@ref17]\] ([Table 1](#table1){ref-type="table"}).

Alternative meshes
------------------

The widespread acceptance of the technique together with concerns regarding the high cost of ADMs has led to the development of alternative synthetic mesh types for use in IBBR \[[@ref18]\].

Ti-LOOP Bra
-----------

TiLOOP Bra (pfm medical titanium, Nuremberg, Germany) is a non-absorbable, titanium coated polypropylene mesh (TCPM), which has been approved for use in breast reconstruction since 2008. It has a knitted monofilament structure and comes available in three different bra-like sizes. Production involves introducing titanium in gaseous form so that it reaches all parts of the mesh, forming covalent bonds with the plastic surface \[[@ref19]\].

SeriSilk
--------

SERIsilk is a silk-derived biological scaffold in which silk filaments are combined by helical twisting to form a multifilament fibre which is purified and then assembled into a three-dimensional scaffold. Laboratory studies have suggested that it behaves more like an ADM in vivo than a Vicryl mesh, in which it is not just absorbed but accompanied by new tissue generation such that the strength and load bearing properties are transferred to the newly ingrown tissue \[[@ref20]\].

TIGR® Matrix Surgical Mesh
--------------------------

TIGR® Matrix is an absorbable, macroporous mesh knotted from two different degradable fibres -- a fast degrading fibre and a slow degrading fibre. The fast degrading fibre is a co-polymer between glycolide and trimethylene carbonate and the slow degrading fibre is a co-polymer between lactide and trimethylene. The idea is that the fast degrading fibre gives extra support during the wound healing phase but is totally resorbed after four months, while the slow absorbing fibre keeps its mechanics up to 6--9 months and is not completely reabsorbed until three years later \[[@ref21]\].

Vicryl mesh
-----------

Vicryl mesh is comprised of polyglactin 910 and is cheap, ready to use and widely available. It also exhibits minimal inflammatory reaction, is non-allergenic and resistant to bacteria biofilm formation. One of the greatest benefits of using Vicryl meshes as an alternative to ADMs is the cost difference, estimated at being two-thirds less \[[@ref22]\].

Benefits of using a mesh as an adjunct in IBBR
----------------------------------------------

There are several reported benefits associated with the use of an ADM in IBBR, which include improved cosmesis, better patient satisfaction, less post-operative pain, less capsular contracture and improved cost-effectiveness (mainly as a result of facilitating one-stage procedures and reducing time to completion of fill in two-stage procedures). Some of these benefits are believed to also be associated with the use of the synthetic meshes but with much less associated cost. Whilst there have been multiple literature and systematic reviews exploring outcomes of ADM use in IBBR, their focus has been predominantly on complication profiles and process evaluation rather than evaluating the available evidence for the benefits of their use \[[@ref23]--[@ref27]\].

Objectives
==========

The purpose of this article is to present a comprehensive and updated review of the literature on the evidence for the benefits of using a mesh in IBBR, compared to reconstructions without a mesh. A secondary aim was to identify any studies which compared the outcomes of using an ADM with an alternative synthetic mesh.

Methods
=======

Search strategy
---------------

We searched the Ovid SP versions of EMBASE and MEDLINE (last updated 01/7/2017) for relevant articles using the search strategy detailed in [Table 2](#table2){ref-type="table"}.

Inclusion criteria
------------------

a.  Studies published from 2007 onwards

b.  Studies reporting on outcomes following the use of a mesh for LPS in IBBR after mastectomy (to include ADMs, all other biologics and synthetic meshes)

c.  Comparative studies only either comparing outcomes between mesh and non-mesh reconstructions or between reconstructions using different mesh types

d.  Clinical outcome studies reporting on at least one of:

    1.  cosmetic outcomes (assessed via an objective method);

    2.  capsular contracture rates (assessed using the Baker scale)

    3.  post-operative pain;

    4.  patient-reported outcomes (using a validated method);

    5.  cost-effectiveness (based on individual patient data not literature review/theoretical).

Exclusion criteria
------------------

a.  Single cohort case series without a comparator

b.  Comparative studies where comparator cohort does not meet the inclusion criteria above

c.  Non-clinical, animal- or lab-based studies

d.  Studies reporting solely on cosmetic or revision procedures

e.  Non-English language articles

f.  Conference abstracts or abstracts without full text available.

Data extraction
---------------

Data extracted from the included papers were author, journal, year of publication, outcome measure(s) described, study type, participants per cohort compared, mesh types used, methodology used, outcomes per cohort and follow-up periods.

Results and Discussion
======================

We identified a total of 12 unique articles that met the inclusion criteria. Of these 10/12 compared ADM-based reconstructions to non-mesh reconstructions, 1/12 compared synthetic mesh (TiLOOP) reconstructions to non-mesh reconstructions and 1/12 compared ADM reconstructions to TiLOOP reconstructions ([Figure 1](#figure1){ref-type="fig"}). There were two RCTs with the remainder being non-randomised comparative retrospective cohort studies. A narrative description of the included studies grouped per mesh type and outcome measure reported is given below.

Evidence for the benefits of using ADMs versus non ADM reconstructions
======================================================================

Evidence for improved cosmesis
------------------------------

We identified four articles meeting the inclusion criteria which compared the cosmetic outcomes between ADM and non-ADM reconstructions \[[@ref28]--[@ref31]\]. All the four studies used panel assessment of standardised clinical post-operative photographs and a validated scoring system, although the specific methodology differed between studies ([Table 3](#table3){ref-type="table"}). The ADM type used was specified in two of the studies as being Alloderm \[[@ref30]\] and both Alloderm and Surgimend \[[@ref28]\], and was unspecified in the remaining two.

All the studies reported that patients in the ADM cohorts had significantly higher overall cosmetic scores compared to the non-ADM cohorts. However, the follow-up period was either not stated per cohort or was significantly different. Given that satisfaction with cosmetic outcomes has been shown to decline over time \[[@ref32]\], this may have had a differential effect on the outcome. Furthermore, the studies were not randomised and there were significant differences between the cohorts at baseline in two of the studies ([Table 3](#table3){ref-type="table"}).

Evidence for improved Patient-Reported Outcome Measures (PROMs)
---------------------------------------------------------------

Two articles compared PROMs between ADM and non-ADM reconstructions using a validated method ([Table 4](#table4){ref-type="table"}) \[[@ref33], [@ref34]\]. McCathy *et al* \[[@ref33]\] randomised patients undergoing two-stage IBBR following mastectomy into receiving Alloderm or not. By using the 'chest and upper body morbidity' domains of the BREASTQ questionnaire as well as a visual analogue scale for postoperative pain, they found no significant difference between the two cohorts either immediately post-operatively or during the expansion phase. However, as described in further detail in the following section, there may have been limitations in the study design/methodology that impacted on these results.

The second study by Hanna *et al* \[[@ref34]\] used the 'Breast Evaluation Questionnaire' to assess whether there was a difference in PROMs between 31 patients who underwent IBBR with Alloderm and 44 patients with total sub-muscular coverage. No significant difference between the two cohorts was demonstrated in all areas of the questionnaire. The only factors identified which influenced the scores were whether reconstructions were bilateral or unilateral and whether patients underwent treatment with radiotherapy or not. In addition to this being a small study, however, the response rate was low overall at 45.3% and there was a difference of over 10 months in length of follow-up between the two cohorts. Furthermore, this was a non-randomised study and there was no stated reason as to why patients were allocated into one cohort or the other.

Evidence for improved pain outcomes
-----------------------------------

McCarthy *et al* \[[@ref33]\], in addition to using the BREASTQ and visual analogue scale for pain described above, objectively evaluated pain outcomes using 24-hour post-operative narcotic use (reported as oral codeine equivalent). They reported no significant difference between the two cohorts in terms of narcotic requirements (p = 0.38). However, the size of the ADM used (4 × 16 cm) was significantly smaller than that generally used in practice, such that the full effect of increased pocket size on reducing pain, particularly during the expansion phase, may not have been realised as a result ([Table 5](#table5){ref-type="table"}).

The second study by Seth *et al* \[[@ref35]\] was a non-randomised retrospective cohort study which compared outcomes between patients having two-stage reconstruction with and without Alloderm. Patients were additionally stratified according to whether or not the patients received post-operative radiotherapy. Post-operative pain was assessed according to whether it had been specifically documented in patient notes on at least one occasion during the period of follow-up. There was no significant difference in reported pain between the cohorts overall. However, when patients were additionally stratified into those who did or did not have post-mastectomy radiotherapy, the non-ADM cohort reported a significantly higher prevalence of pain in the radiotherapy group, whereas no difference was seen in the ADM cohort. Although the sample size is small, the authors suggest this difference may be a consequence of the protective effect of the ADM in reducing capsular contracture.

Evidence for reduced levels of capsular contracture
---------------------------------------------------

Despite encouraging evidence from single cohort case series which report very low rates of capsular contracture when compared to pre-existing data from non-ADM cohorts \[[@ref36], [@ref37]\], only two comparative studies were identified that met the inclusion criteria \[[@ref29], [@ref30]\] ([Table 6](#table6){ref-type="table"}). Vardanian *et al* \[[@ref30]\] performed a retrospective comparison of the outcomes of two-stage reconstruction with or without the use of Alloderm ADM in 203 patients and reported a significantly lower rate of capsular contracture (Baker grade III or IV) in the ADM cohort at a mean follow-up of 29 months (3.8% versus 19.4% p \< 0.001). A second study by Forsberg *et al* \[[@ref29]\] also found capsular contracture was significantly lower, although the ADM type used was not specified (8.1% versus 23.5% p = 0.048).

Both of these comparative studies have potential sources of bias, however, which limit how far their results can be accepted. Both the studies were retrospective and based on case note review alone as opposed to prospective and standardised evaluation of Baker grade of contracture. Furthermore, capsular contracture rate is known to increase over time and both the studies had short median follow-up periods, which was significantly less in the ADM cohort in the study of Forsberg *et al* \[[@ref29]\] and was not reported on a per cohort basis in the study of Vardanian *et al* \[[@ref30]\].

Evidence for cost--benefits
---------------------------

Three non-randomised comparative cohort studies addressed the question of a cost--benefit when comparing ADM reconstructions with non-ADM reconstructions. Three additional articles were identified but were excluded as they used literature searches/systematic reviews to pool data on outcomes from case series rather than using patient level data \[[@ref38]--[@ref40]\]. All three included studies used different methodologies ([Table 7](#table7){ref-type="table"}).

Two studies evaluated the cost of using Strattice in a single-stage procedure. Johnson *et al* \[[@ref41]\] compared the costs of both unilateral and bilateral reconstructions with two-stage tissue expander/implant (TE/I) reconstructions without ADM or one-stage latissimus dorsi (LD) flap + implant reconstructions. They used NHS tariffs as a proxy for actual costs incurred together with the acquisition costs for the Strattice mesh. They reported that for unilateral reconstructions, there was a cost advantage of using Strattice compared to the other two techniques. Specifically, when compared to two-stage TE/I reconstructions, a one-stage Strattice reconstruction eliminated costs associated with outpatient visits for expansions and a second procedure for implant exchange. When compared to LD + implant reconstructions, the lack of additional donor site morbidity and outpatient visits for seroma drainage also resulted in a cost advantage.

Kilchenmann *et al* \[[@ref42]\] alternatively used 'resource allocation' rather than direct costs to compare unilateral one-stage reconstructions with Strattice to two-stage TE/I reconstructions; two-stage LD-TE/I reconstructions and one-stage LD flap + implant reconstruction. In agreement with Johnson *et al* \[[@ref41]\], they also demonstrated a cost advantage to the single-stage approach which offsets the additional cost of the mesh. However, when compared to the one-stage LD + implant reconstructions, they found the costs were equivalent.

Bank *et al* \[[@ref43]\] used the number of expansions required to achieve final expander fill volume as a proxy for the number of outpatient clinics attended post-operatively by patients undergoing uncomplicated ADM- and non-ADM two-stage TE/I reconstructions, in order to determine whether there was a difference in direct hospital costs. Although they found ADM reconstructions had indeed reduced the number of outpatient visits and associated costs, this was insufficient to offset the elevated material costs of using an ADM.

Without a standardised means of performing a cost analysis, it is difficult to be certain from these three studies as to whether use of an ADM results in a cost advantage over other techniques. Furthermore, longer term follow-up including details of revision surgery and quality-of-life data is required in order to perform a full assessment.

Evidence for the benefits of using synthetic meshes versus non-mesh reconstructions
===================================================================================

We identified no comparative studies reporting on the outcomes of interest for SeriSilk, TIGR matrix or Vicryl meshes in IBBR.

One retrospective, non-randomised cohort study reported on the difference in outcomes between reconstructions with or without the use of a TiLOOP bra mesh ([Table 8](#table8){ref-type="table"}). Dieterich *et al* \[[@ref44]\] compared 42 patients with a TiLOOP mesh to 42 who underwent a non-mesh reconstruction, using the BREASTQ post-reconstruction questionnaire. Analysis of responses showed no significant differences between the groups in all of the domains of the BREASTQ. However, stepwise linear regression showed a negative association of the 'satisfaction with breasts' domain with the use of the TiLOOP bra. Reasons for this difference may have been multifactorial, however. The way in which patients were selected into the TiLOOP cohort depended on intra-operative findings such as adequacy of soft tissue coverage; comparison of the two groups at baseline showed that the patients in the TiLOOP cohort had significantly lower BMIs and were significantly younger -- both factors which have an impact on expectations of aesthetic outcome.

Capsular contracture rates were additionally compared between the two cohorts with 7/42 in the non-TiLOOP group and 2/42 in the TiLOOP, developing a Baker III/IV contracture during the period of follow-up (p = 0.052). Cosmesis, post-operative pain and costs were not compared between the two cohorts.

Studies comparing outcomes of reconstructions using ADMs versus synthetic meshes
================================================================================

A single study was identified which compared outcomes (complications, cosmesis and PROMs) between synthetic mesh and ADM reconstructions \[[@ref45]\]. Gschwantler *et al* \[[@ref45]\] performed a prospective, randomised multicentre pilot study in which patients undergoing immediate breast reconstruction were allocated to receiving TiLOOP or a porcine ADM (Protexa). Patients in the ADM cohort differed significantly from the TiLOOP cohort at baseline in terms of exposure to radiotherapy and also in terms of rates of reconstructive failure (protexa n = 7 30.4%; TiLOOP n = 2 7.7%).

Cosmetic outcomes were again scored using standardised post-operative photographs at six months using the four point Harris scale, by four surgeons and two external experts. They reported that cosmetic scores were significantly higher in the TiLOOP cohort. However, the ADM cohort had a significantly higher proportion of reconstructive failures, and when these cases were removed from the analysis there was no longer any significant differences found in terms of cosmesis.

Patient-reported outcomes were assessed using the EORTC QLQ C30 and BR23 questionnaires. Significantly lower scores were reported in the ADM cohort at the first post-operative visit for arm pain (p = 0.039) and fatigue (p = 0.03) and at six months for effect on family life (p = 0.021) and sexual interest (p = 0.039)

Given the small numbers of patients compared, and the unusually high rate of reconstructive failure in the ADM cohort, it is difficult to draw any clear conclusions from this study.

Conclusions
===========

Despite the popularity of using meshes as adjuncts to support the lower pole in implant-based reconstruction, this review has demonstrated a significant paucity of evidence to support the reported benefits of their use. Where there is evidence available, this is primarily for the use of ADMs rather than the newer synthetic meshes and is mainly derived from retrospective cohort studies. The need to demonstrate equivalent or superior outcomes with the use of synthetic meshes compared to ADMs is an important consideration, given that they are much less expensive to produce. Furthermore, without high-quality comparative data it is impossible for surgeons to know which mesh they should use in order to give the greatest benefit to their patients.

Previous literature reviews have focused on the complication and safety profiles of the meshes used in breast reconstruction as the primary outcome measures of interest \[[@ref46]--[@ref50]\]. Given that the primary purpose of breast reconstruction surgery is to improve psychosocial functioning and body image, it is perhaps equally important that outcomes such as cosmesis and patient satisfaction are also included as a means of evaluating the success of the technique \[[@ref51]\]. One of the problems with this, however, is that there is as yet no agreed method by which cosmesis, PROMs and cost-benefit should be assessed objectively. Current methods used to evaluate cosmesis, as reported in this review, which involve a panel review of post-operative photographs are associated with a degree of subjectivity and inter-assessor variability \[[@ref52]\].

The majority of the evidence base for use of meshes in implant-based reconstruction is composed of either single-cohort case series or retrospective cohort studies \[[@ref53]\]. Ideally, well-designed prospective cohort studies or RCTs with sufficient periods of follow-up should be carried out to determine whether the cost of these products is justified in terms of the benefits provided. The iBRA study (implant-based Breast Reconstruction evaluAtion) is a UK multicentre audit which is designed to explore the practice and outcomes of implant-based reconstructions \[[@ref54]\]. Data derived from this study will not only provide a large amount of prospective data but will help to inform the design of any future trials in this area.
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###### ADMs and synthetic meshes commonly used in IBBR.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                       Product name                                                                                                     Source/material                                            Details
  ------------------------------ ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------------------------
  **ADM**                        Alloderm                                                                                                         Human dermis                                               Freeze-dried, aseptic, requires refrigeration and rehydration prior to use

  Alloderm RTU                   Sterile, pre-hydrated, two-minute soak only                                                                                                                                 

  Alloderm contour fenestrated   Sterile, pre-hydrated, crescent shape to ease use and fenestrated to allow passage of any periprosthetic fluid                                                              

  FlexHD                         Pre-hydrated                                                                                                                                                                

  DermaMatrix                    Freeze-dried aseptic, requires rehydration                                                                                                                                  

  CGDerm                         Freeze dried, requires 20 minutes' rehydration                                                                                                                              

  CGCryoDerm                     Frozen but not dried, only required three minutes' soak in saline                                                                                                           

  Strattice                      Porcine dermis                                                                                                   Sterile                                                    

  Protexa                        Porcine dermis                                                                                                   Sterile                                                    

  Surgimend                      Bovine dermis                                                                                                    Sterile                                                    

  **Other biologics**            Veritas\                                                                                                         Bovine pericardium\                                        Fenestrated mesh made of decellularised pericardium\
                                 Meso BioMatrix                                                                                                   Porcine preitoneum                                         Derived from porcine mesothelium

  **Synthetic mesh**             TiLOOP bra                                                                                                       Titanised polypropelene                                    Non-absorbable mesh

  TIGR mesh                      Absorbable mesh                                                                                                  Macropourous mesh made of two types of co-polymer fibres   

  Vicryl Mesh                    Absorbable mesh                                                                                                  Dissolves rather than integrates into tissue               

  **Other materials**            SERI silk                                                                                                        Multifilament silk mesh                                    Behaves like an ADM *in vivo* allowing in-growth of new tissue
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Search strategy.

  No   Term
  ---- ----------------------------------------------------------------------
  1    Breast/
  2    Breast.mp
  3    1 or 2
  4    Biocompatible materials/
  5    ADM.mp
  6    Acellular derm\* .mp
  7    strattice.mp
  8    Surgimend.mp
  9    Dermamatrix.mp
  10   Alloderm.mp
  11   Allomax.mp
  12   FlexHD.mp
  13   TIGR mesh.mp
  14   TiLOOP.mp
  15   Veritas.mp
  16   Seri.mp
  17   4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
  18   Reconstructive surgical procedures/
  19   'Prostheses and implants'/
  20   Breast implants/
  21   Tissue expansion devices/
  22   Implant\*.mp
  23   Expand\*.mp
  24   Prosthe\*.mp
  25   Surgery, plastic/
  26   18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
  27   3 and 17 and 26
  28   Limit 27 to Humans, English Language
  29   Remove duplicates

###### Cosmetic outcome studies -- ADM versus non-ADM cohort.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                               Cohorts compared                                               Variables compared at baseline                                        Assessors/method used                                                                                                             Follow-up period/time of assessment                                                           Method of evaluation                                                                                                        Results
  ------------------------------------ -------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Ibrahim *et al* \[28\], 2015**     ADM (Alloderm or Surgimend) n = 18 patients\                   Yes NSD                                                               Panel assessment of pre-/post-operative photographs by five plastic surgeons not directly involved in care and blinded            Six months to seven years (1.7 years) Not compared between groups                             Scored using validated subscales for volume; contour; placement of implant; scars; lower pole projection; IMF definition    ADM cohort scored statistically significantly higher in terms of overall cosmetic outcome and for subscales for contour and implant placement
                                       Non-ADM n = 20 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Forsberg *et al* \[29\], 2014**    ADM (type not specified) n = 58 reconstructions\               Yes -- significantly more delayed reconstructions in non-ADM cohort   Panel assessment of post-operative photographs; 18 blinded assessors (six plastic surgeons; six trainees; six medical students)   ADM: 25 months\                                                                               Scored using validated subscales for contour; symmetry of shape; symmetry of size; position and overall outcome             ADM cohort received higher scores for all parameters in each group of assessors. Difference reached significance for majority
                                       Non-ADM n = 125 reconstructions                                                                                                                                                                                                                                        Non-ADM: 34 months\                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                              Significant difference p = 0.005                                                                                                                                                                                          

  **Nguyen *et al* \[31\], 2012**      ADM (type not specified) n = 53 patients\                      Yes -- significantly higher BMI in ADM cohort                         Panel assessment of post-operative photographs; three plastic surgeons not involved in care; blinded                              Not specified, although photographs taken at least 90 days following second-stage procedure   Scored using validated subscales for volume; contour; placement of implant; scars; lower pole projection; IMF definition    ADM cohort scored statistically significantly higher in terms of overall cosmetic outcome and for subscales for volume, IMF definition and implant placement
                                       Non-ADM n = 58                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Vardanian *et al* \[30\], 2011**   ADM (Alloderm) n = 208 reconstructions\                        Yes NSD                                                               Panel assessment of post-operative photographs; four blinded assessors -- surgeon, secretary and two medical students             Not stated -- all post-implant exchange                                                       Four-point Harris scale for overall aesthetic outcome and IMF placement (1 -- poor; 2 -- fair; 3 -- good; 4 -- excellent)   Score for both overall aesthetic outcome and IMF placement significantly higher in ADM cohort
                                       Non-ADM -- partial (n = 119) and total (n = 10) sub-muscular                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**NSD: no significant difference.**

###### Studies comparing PROMs between ADM versus non-ADM reconstructions.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                             Methods/materials compared       Selection into cohort                     Validated PROMS instrument used/subscales                                                              Response rate                      Follow-up period                                                                                                    Results                                                                                                  Comments
  ------------------------------------- -------------------------------- ----------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  McCarthy *et al* \[[@ref33]\], 2012   ADM: Alloderm n = 36 patients\   Randomised                                The Physical Well-being: chest and upper body domain of the BREASTQ pre-/post-reconstruction module\   100%                               Immediately post-operatively; following the 1st--3rd post-op expansions and immediately prior to implant exchange   No significant difference in scores for either BREASTQ or VAS at all stages of reconstruction measured   Recruitment stopped early due to slow accrual. Smaller sized mesh used than is generally used in current practice
                                        Non-ADM: n = 33 patients                                                   Visual analogue scale\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                   Prospective                                                                                                                                                                                                                                                                                                                                                            

  Hanna *et al* \[[@ref34]\], 2013      ADM: Alloderm n = 31 patients\   Method not stated, consecutive patients   Breast Evaluation Questionnaire (phone assessment), retrospective                                      45.3%\                             ADM 10.2 +/- 7.7 m\                                                                                                 No significant difference between the two cohorts in terms of responses to all questions.                Low response rate and small patient population
                                        Non-ADM n = 44                                                                                                                                                                    Rate between groups not compared   TSR 20.7 +/- 11 m\                                                                                                                                                                                                           
                                                                                                                                                                                                                                                             No p value stated                                                                                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Studies comparing pain outcomes between cohorts.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                             Methods/materials compared         Selection into cohort   Method of pain assessment                                                               Results                                                                                                    Follow-up period (timing of assessment)                                                                               Conclusions
  ------------------------------------- ---------------------------------- ----------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  McCarthy *et al* \[[@ref33]\], 2012   ADM: Alloderm\                     Randomised              PROMS (see [Table 2](#table2){ref-type="table"})\                                       No significant difference in scores for either BREASTQ or VAS at all stages of reconstruction measured.\   Immediately post-operatively, following the 1st--3rd post-op expansions and immediately prior to implant exchange.\   No evidence for reduction in post-operative pain with use of an ADM either immediately or in the expansion phase of two-stage breast reconstruction
                                        n = 36 patients\                                           24-hour post-operative narcotic use (reported as oral codeine equivalent)               No significant difference in post-operative narcotic requirements p = 0.38                                 24 hours post-operatively                                                                                             
                                        Non-ADM:\                                                                                                                                                                                                                                                                                                                                                                           
                                        n = 33 patients                                                                                                                                                                                                                                                                                                                                                                     

  Seth *et al* \[[@ref35]\], 2012       ADM: Alloderm/Flex HD\             Not stated              Recorded if documented by surgeon following at least one subjective patient complaint   ADM: Pain documented for five patients (2.5%) and for ten non-ADM patients (2.5%)\                         ADM 23.2 +/− 8.9 months (3--45)\                                                                                      Authors suggest that this differential effect of radiotherapy on pain may be a consequence of the protective effect of the ADM due to reduced capsular contracture
                                        N = 199 breasts/137 patients\                                                                                                                      p = 0.60.\                                                                                                 Non ADM24.4 +/− 12.7 (4--49) p = 0.23                                                                                 
                                        No ADM 393 breasts/280 patients\                                                                                                                   No difference in the ADM cohort when stratified\                                                                                                                                                                                 
                                                                                                                                                                                           according to radiotherapy exposure; significantly\                                                                                                                                                                               
                                                                                                                                                                                           more patients reported pain if exposed to radiotherapy in the non-ADM cohort                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Comparative studies evaluating capsular contracture (cc) rates (ADM versus Non-ADM).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                              Groups compared                                                Variables                                                                                                                                                                                                                                        Method of assessment                                                                            Follow-up period                                                                              Results
  -------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Vardanian *et al* \[[@ref30]\], 2011   ADM (Alloderm)\                                                No significant difference (NSD) between cohorts in terms of age, BMI, smoking and indication for reconstruction                                                                                                                                  Retrospective chart review of recorded Baker score. Considered significant if Baker III or IV   Median 29 months post-implant exchange for both cohorts -- not compared. Range not reported   Overall cc rates: ADM 3.8%; non-ADM 19.4% p \< 0.001.\
                                         n = 208\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      On multivariate analysis\
                                         Non-ADM -- partial (n = 119) and total (n = 10) sub-muscular                                                                                                                                                                                                                                                                                                                                                                                                                                                  ADM use associated with significantly lower cc rates (OR 0.18; 95% CI 0.08--0.43)

  Forsberg *et al* \[[@ref29]\], 2014    ADM (type not specified) n = 58\                               NSD between cohorts in terms of age, BMI, smoking, diabetes, adjuvant therapy, implant type (saline/silicone) or size. Significant difference in the number of immediate reconstructions (higher in ADM cohort) and length of follow-up period   Retrospective chart review of recorded Baker score. Considered significant if Baker III or IV   ADM 24.6 months\                                                                              Significant difference in cc rates:\
                                         Non-ADM n = 125                                                                                                                                                                                                                                                                                                                                                                                                 Non-ADM 33.8 months\                                                                          ADM: 8.1%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                         p = 0.005                                                                                     Non-ADM 23.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       P = 0.048
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Studies comparing cost-effectiveness (ADM versus Non-ADM).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                            Study type                            Reconstructions compared                              Method                                                                                                                 Factors included                                                                                                                                  Results
  ------------------------------------ ------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Johnson *et al* \[[@ref41]\], 2013   Single-centre cohort, retrospective   Strattice: bilateral (n = 13), unilateral (n = 11)\   Use of National Tariffs (NHS England 2011--2012) as a proxy for hospital costs plus acquisition costs for Strattice    Cost of index operation, consumables in addition to those accounted for in-tariff payment, admissions and attendances and complications           For unilateral cases, Strattice is less costlier than TE/I (£3685 vs. £4985) and LD-based reconstructions (£3685 vs. £6321)\
                                                                             TE/I: bilateral n = 12, unilateral n = 10\                                                                                                                                                                                                                                                                                     For bilateral cases, Strattice is costlier than TE/I due to anomaly in reimbursement system where bilateral mastectomy does not attract any higher reimbursement than unilateral
                                                                             LD + implant n = 10                                                                                                                                                                                                                                                                                                            

  Kilchenmann *et al* \[[@ref42]\],\   Single-centre cohort, retrospective   Unilateral reconstructions only\                      Use of resources utilised rather than costs incurred                                                                   Cost of initial operation, additional hospitalisations and operative procedures; outpatient appointments, seroma aspiration, complication rates   Unilateral single-stage ADM reconstructions were associated with fewer resources utilised compared to TE/I and LD/TE/I in both complicated and non-complicated cases over a 24-m period. LD + mplantI and ADM cohorts equivalent
  2014                                                                       Strattice one-stage n = 25\                                                                                                                                                                                                                                                                                                    
                                                                             TE/I n = 27\                                                                                                                                                                                                                                                                                                                   
                                                                             LD+ implant n = 32\                                                                                                                                                                                                                                                                                                            
                                                                             LD/TE n = 17                                                                                                                                                                                                                                                                                                                   

  Bank *et al* \[[@ref43]\], 2013      Single-centre, retrospective          Uncomplicated reconstructions only\                   Number of tissue expansions required to meet final fill volume as a proxy for number of outpatient clinic encounters   Total cost of each clinic encounter using expenditure data from centre (faculty fees, labour fees, material costs). Cost of ADM                   Although fewer clinic visits are required to achieve final fill volume in ADM cohort the savings made did not offset the cost of using an ADM. Difference of \$3000 remained if Alloderm is used and \$2500 if Strattice
                                                                             TE/I with ADM (Strattice or Alloderm) *n* = 84\                                                                                                                                                                                                                                                                                
                                                                             Non-ADM TE/I *n* = 48                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Study comparing PROMS between synthetic mesh (TiLOOP) and non-mesh reconstruction.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                              Methods/materials compared   Selection into cohort                                                                Validated PROMS instrument used/subscales                                                      Response rate             Follow-up period          Results                                                                                                                                                                                               Comments
  -------------------------------------- ---------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- ------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Dieterich *et al* \[[@ref44]\], 2015   TiLOOP bra n = 42\           Specific selection into TiLOOP cohort was based on decision made intra-operatively   BREASTQ -- post-reconstruction module (all subscales) -- postal questionnaire, retrospective   67.7%\                    TiLOOP 18 m (1--40)\      No significant differences between the groups in all of the domains. However, stepwise linear regression showed a negative association with "satisfaction with breasts" scores in the TiLOOP cohort   Surgeon selection into cohort and significant differences between two groups in terms of BMI and age
                                         Non-mesh -- n = 42\                                                                                                                                                                                              NSD between two groups\   No mesh 17.5 m (1--83)\                                                                                                                                                                                                         
                                         Retrospective cohort                                                                                                                                                                                             p = 0.117                 P = 0.827                                                                                                                                                                                                                       

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
